Scinai Immunotherapeutics Ltd. has acquired Recipharm Israel for an undisclosed amount. This corporate acquisition sees Scinai Immunotherapeutics taking ownership of Recipharm Israel, a contract development and manufacturing organization (CDMO) specializing in small molecule active pharmaceutical ingredient (API) development and manufacturing. Recipharm Israel is a part of Recipharm, a global CDMO dedicated to meeting pharmaceutical companies’ evolving needs through operational excellence, scientific know-how, and customer connectivity.
Recipharm Israel offers a comprehensive, one-stop solution for small molecule development and API clinical supply. Its services encompass custom synthesis, route scouting, process development, analytical development and validation, and the provision of reference samples. The company also supplies APIs for toxicology and human studies, conducts ICH stability studies, and provides comprehensive reports and GMP documentation. Its team of experts supports product development at every stage of the lifecycle.
This acquisition is strategically significant for Scinai Immunotherapeutics. By integrating Recipharm Israel's specialized capabilities, Scinai aims to enhance its internal drug development and manufacturing capacities, potentially streamlining its supply chain and accelerating the progression of its therapeutic candidates. The expertise in small molecule API development and manufacturing brought by Recipharm Israel is expected to create synergies, offering Scinai greater control over critical aspects of its product pipeline and potentially reducing reliance on external partners for key manufacturing stages.
The integration of Recipharm Israel's established CDMO operations into Scinai Immunotherapeutics is anticipated to strengthen Scinai's overall operational framework. This move positions the combined entity to potentially optimize development timelines and manufacturing efficiencies, supporting future growth and the advancement of its therapeutic portfolio.